Truist analyst Tobey Sommer lowered the firm’s price target on AMN Healthcare (AMN) to $40 from $47 but keeps a Buy rating on the shares. The competitive environment is beginning to show modest signs of stability to slight upwards slope, with December quarter sales topping consensus by 2.6% ex-strike – the largest upside variance since Q4 of 2022, while Q1 guidance was 1.8% below consensus on a normalized basis, the analyst tells investors in a research note. The recent launch of WorkWise should drive a robust pipeline of labor disruption revenue, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- Cautious Outlook on AMN Healthcare Services Amid Lower Guidance and Contract Labor Challenges
- AMN Healthcare Reports 2024 Financial Results and Outlook
- Closing Bell Movers: Booking gains 3%, Akamai down 8% on earnings
- AMN Healthcare sees Q1 revenue $660M – $680M , consensus $657.8M
- AMN Healthcare reports Q4 EPS 75c, consensus 49c